E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Uncomplicated cystitis in adult, non pregnant women, age 18-60. |
Ukomplisert cystitt hos voksne, ikke-gravide kvinner, alder 18-60. |
|
E.1.1.1 | Medical condition in easily understood language |
Cystitis in women |
Blærekatarr hos kvinner |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000699 |
E.1.2 | Term | Acute cystitis (excl in pregnancy) |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Although uncomplicated cystitis is considered to be a mild condition and mostly self limiting, most patients who see a doctor will be treated with antibiotics. Antibiotics are known to give a quick relief of symptoms and shorten the course of the condition by a few days.
The aim of this study is to evaluate ibuprofen versus mecillinam in the treatment of uncomplicated cystitis in otherwise healthy, non-pregnant women.
Our main objective is to see whether symptomatic treatment with ibuprofen is equally efficiant as treatment with mecillinam in this group. |
Selv om ukomplisert cystitt er ansett å være en mild og for det meste selvbegrensende tilstand, vil de fleste pasienter som oppsøker lege på grunn av dette bli behandlet med antibiotika. Antibiotika vil gi en rask symptomlindring samt forkorte sykdomsforløpet. Formålet med denne studien er å evaluere ibuprofen versus mecillinam i behandlingen av ukomplisert cystitt hos voksne, ikke-gravide kvinner. Vi ønsker å se om ibuprofen vil være et likeverdig behandlingsalternativ til mecillinam i denne gruppen. |
|
E.2.2 | Secondary objectives of the trial |
Will it take longer for the patients in the ibuprofen group to feel well? Are there more complications in the ibuprofen group compared to the mecillinam group? Are they more likely to develop an upper urinary tract infection? Are they more likely to develop a second uncomplicated cystitis within the four weeks of follow up? Are there more positive urine cultures in the ibuprofen group after two weeks? |
Vil det ta lengre tid før pasientene i ibuoprofengruppen føler seg friske? Er det mer komplikasjoner i ibuprofengruppen sammenlignet med mecillinamgruppen? Har disse pasienten økt risiko for å utvikle en øvre urinveisinfeksjon? Har de økt risiko for å utvikle en ny ukomplisert cystitt i løpet av oppfølgingsperioden på fire uker? Er det flere positive urinkulturer i ibuprofengruppen etter to uker? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Woman between 18 and 60 years of age.
Dysuria and urinary frequency and/or urinary urgency.
Ability to speak, understand and write Norwegian/Swedish/Danish and ability to give consent.
|
Kvinne mellom 18 og 60 år.
Smerter/svie ved vannlating og hyppig vannlating eller økt trang til å late vannet.
Snakker, forstår og skriver godt norsk/svensk/dansk og samtykkekompetent
|
|
E.4 | Principal exclusion criteria |
Pregnancy/breastfeeding child under one month of age
Diabetes
Kidney disease or use of the drug probenecid
Clinical suspicion of pyelonefritis; fever, reduced general condition, upper back pain
Vaginal symptoms such as discharge or irritation
Severe abdominal pain
Symptoms that have lasted for more than seven days
One or more urinary tract infections within the lasts four weeks
Permanent bladder catheter or use of bladder catheter within the last four weeks
Use of antibiotics within the last two weeks
Previous allergic reaction to penicillin
Previous allergic reaction to ibuprofen, or worsening of asthma when taking NSAIDs
Narrow oesophagus
Severe gastritis or previous ulcer
Anticoagulative treatment
Ongoing use of steroids
Use of immunosuppressant drugs
Thrombocytopenia
Heart insufficiency
Severe psychiatric illness or dementia
Severe drug addiction
Unable to communicate in Norwegian, Swedish or Danish language |
Gravid/ammer barn under 1 måned
Sukkersyke
Nyresykdom eller bruk av mdeisinen probenecid
Symptomer på nyrebekkenbetennelse; feber, redusert almenntilstand, smerter øvre del rygg/mage
Mye utflod, kløe og irritasjon i underlivet eller sterke smerter i magen
Plager som har vedvart i over syv dager
Urinveisinfeksjon (øvre/nedre) eller brukt urinveiskateter de siste fire uker
Bruk av antibiotika i løpet av de siste to uker
Tidligere allergisk reaksjon på penicillin
Tidligere allergisk reaksjon eller astmaforverring ved bruk av ibuprofen
Trangt spiserør
Antikoagulasjonsbehandling
Trombocytopeni
Alvorlig gastritt eller tidligere magesår
Pågående bruk av steroider
Immunsuppressiv behandling
Hjertesvikt
Demens, alvorlig psykiatrisk lidelse eller alvorlig rusmisbruk
Manglende evne til å kommunisere muntlig og skriftlig på norsk/svensk/dansk |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients who feel cured by day four as registered in the patient diary |
Andel pasienter som føler seg friske innen fire dager, som registrert i pasientdagbok. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The patients’ symptom load with regard to specific symptoms.
Proportion of patients who had a relapse of symptoms of uncomplicated cystitis within the study period.
Proportion of patients who were in need of a secondary medical consult within the study period.
Proportion of patients who developed an upper urinary tract infection (pyelonefritis).
Proportion of patients who experienced severe adverse effects.
Proportion of patients with a positive urine culture after two weeks. |
Pasientenes symptomstyrke med hensyn til spesifikke sympotmer.
Andel pasienter som opplevde residiv av symptomer på ukomplisert cystitt i løpet av studieperioden.
Andel pasienter som hadde behov for en ny legekonsultasjon i løpet av studieperioden.
Andel pasienter som utviklet en øvre urinveisinfeksjon (pyelonefritt).
Andel pasienter som opplevde alvorlige bivirkninger.
Andel pasienter med positiv urinkultur etter to uker. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
We will end the trial when a sufficient number of patients have been included according to the power calculation, i.e. 400 patients in total, 200 in Oslo and 70 at each of the other three study sites. End of trial is four weeks after the visit of the last subject undergoing the trial since the follow up of the subject is four weeks after inclusion in the trial.
|
Vi avslutter studien når vi har inkludert et tilfredsstillende antall pasienter i følge styrkeberegning, dvs 400 pasienter, 200 pasienter i Oslo og ca 70 ved hvert av de andre studiestedene. Vi avslutter datainnsamlingen fire uker etter at siste pasient er inkludert, dette er på grunn av at siste kontakt med pasientene er fire uker etter de ble inkludert. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |